Payment overview · 2025
General Payments
$76,024.63
53 reported records · 7 companies
Healthcare provider profile · identity verified
Marcus Anthony Urey, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Advanced Heart Failure and Transplant Cardiology · SAN DIEGO, CA · NPI 1972820058
Verified facts
What the public records show
CMS Open Payments records show Marcus Anthony Urey, MD received $76,024.63 in general payments during 2025 across 53 reported records.
BridgeBio Pharma, Inc. accounted for 57.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Wainua.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported WAINUA as an associated drug or biological on 13293 records involving 7069 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wainua by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $44,004.59 | 57.9% | 22 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20,728.90 | 27.3% | 13 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $9,983.27 | 13.1% | 9 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $839.68 | 1.1% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $399.85 | 0.5% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $49.27 | 0.1% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.07 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $49,630.38 | 18 |
| Consulting Fee | $19,261.50 | 6 |
| Travel and Lodging | $5,818.04 | 12 |
| Food and Beverage | $1,314.71 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $44,004.59 | 22 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $19,117.90 | 12 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $7,015.73 | 5 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $279.73 | 2 | 2025 |
Source payment records
|
|||||
| 2ND GEN CENTRIMAG PRIMARY CONSOLE Normalized: 2nd gen centrimag primary console |
Device | Abbott Laboratories | $120.12 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $55.87 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| WAINUA wainua |
2025 | Wainua | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
115 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | WAINUA open payments reported associated product |
CMS Open Payments — General Payments 13293 supporting records · 7069 recipient NPIs · example record 1206131360 |
Wainua · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vyndamax | Tafamidis | 353 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 337 | 99 |
| Jardiance | Empagliflozin | 336 | 85 |
| Spironolactone | Spironolactone | 197 | 61 |
| Sirolimus | Sirolimus | 193 | 42 |
| Eliquis | Apixaban | 173 | 40 |
| Bumetanide | Bumetanide | 168 | 61 |
| Famotidine | Famotidine | 151 | 39 |
| Losartan Potassium | Losartan Potassium | 143 | 46 |
| Entresto | Sacubitril/Valsartan | 139 | 41 |
| Nifedipine Er | Nifedipine | 130 | 30 |
| Tacrolimus | Tacrolimus | 124 | 37 |
| Potassium Chloride | Potassium Chloride | 117 | 37 |
| Farxiga | Dapagliflozin Propanediol | 115 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 114 | 35 |
| Carvedilol | Carvedilol | 112 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 93 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 88 | 18 |
| Envarsus Xr | Tacrolimus | 86 | 15 |
| Allopurinol | Allopurinol | 81 | 21 |
| Gabapentin | Gabapentin | 78 | 21 |
| Trulicity | Dulaglutide | 75 | 12 |
| Atorvastatin Calcium | Atorvastatin Calcium | 73 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 23 |
| Lisinopril | Lisinopril | 68 | 17 |
| Trazodone Hcl | Trazodone Hcl | 68 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 18 |
| Furosemide | Furosemide | 56 | 24 |
| Torsemide | Torsemide | 51 | 14 |
| Omeprazole | Omeprazole | 46 | 11 |
| Prednisone | Prednisone | 45 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 44 | 15 |
| Vyndaqel | Tafamidis Meglumine | 43 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 12 |
| Sertraline Hcl | Sertraline Hcl | 39 | 11 |
| Ezetimibe | Ezetimibe | 38 | 14 |
| Lansoprazole | Lansoprazole | 38 | suppressed |
| Mirtazapine | Mirtazapine | 33 | 11 |
| Finasteride | Finasteride | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | suppressed |
| Atovaquone | Atovaquone | 30 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | 11 |
| Valsartan | Valsartan | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | suppressed |
| Valganciclovir Hcl | Valganciclovir Hcl | 27 | 15 |
| Colchicine | Colchicine | 25 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Eplerenone | Eplerenone | 23 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | 14 |
| Amoxicillin | Amoxicillin | 22 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | suppressed |
| Repatha Syringe | Evolocumab | 21 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Arcalyst | Rilonacept | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Metformin Hcl | Metformin Hcl | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Wainua | Eplontersen Sodium | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Entecavir | Entecavir | 11 | suppressed |
| Everolimus | Everolimus | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $76,024.63 · 53 records | BridgeBio Pharma, Inc. | 2ND GEN CENTRIMAG PRIMARY CONSOLE, AMVUTTRA, Attruby, FUROSCIX, ONPATTRO, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, WAINUA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Wainua play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error